Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr 5;10(4):202.
doi: 10.3390/diagnostics10040202.

In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends

Sandeep Kumar Vashist  1
Affiliations
Editorial

In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends

Sandeep Kumar Vashist. Diagnostics (Basel). .

Abstract

There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformité Européenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19.

Keywords: COVID-19; SARS-CoV-2; diagnostics; immunoassays; lateral flow immunoassay (LFIA); point-of-care (POC); real-time reverse transcriptase polymerase chain (RT-PCR).

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Schematic of the SARS-CoV-2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. [(accessed on 2 April 2020)]; Available online: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594....
    1. COVID-19 coronavirus Pandemic. [(accessed on 2 April 2020)]; Available online: https://www.worldometers.info/coronavirus/
    1. Phelan A.L., Katz R., Gostin L.O. The novel coronavirus originating in Wuhan, China: Challenges for global health governance. JAMA. 2020;323:709–710. doi: 10.1001/jama.2020.1097. - DOI - PubMed
    1. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7. - DOI - PMC - PubMed
    1. Chan JF W., Kok K.H., Zhu Z., Chu H., To KK W., Yuan S., Yuen K.Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 2020;9:221–236. doi: 10.1080/22221751.2020.1719902. - DOI - PMC - PubMed

Publication types

LinkOut - more resources

-